Barbara Burtness, MD, is Professor of Medicine at the Yale University School of Medicine. She is co-leader of the Developmental Therapeutics Program and director of the Head and Neck Clinical Research Program at Yale Cancer Center. Dr. Burtness graduated with an MD from the State University of New York at Stony Brook. She completed her internship and residency at Yale-New Haven Hospital and fellowship training in oncology at Memorial Sloan-Kettering Cancer Center.
Dr. Burtness' research focuses on translational studies in head and neck cancer, including biomarkers of resistance to EGFR inhibition, synthetic lethal approaches for HPV-negative head and neck cancer, and immunotherapy. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicenter trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers. She has conducted numerous phase 1 through 3 investigator-initiated trials of targeted therapy and immune checkpoint inhibition.
Dr Burtness co-edits the text Molecular Determinants of Head and Neck Cancer and is editor
in chief of the journal Cancers of the Head and Neck. She has published over 190 peer-reviewed articles.